Waldencast (NASDAQ:WALD – Get Free Report) will be releasing its earnings data after the market closes on Tuesday, August 27th. Analysts expect Waldencast to post earnings of ($0.03) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.
Waldencast Trading Up 7.0 %
WALD opened at $2.91 on Tuesday. Waldencast has a 12 month low of $2.40 and a 12 month high of $12.00. The stock has a 50-day moving average of $3.41 and a 200 day moving average of $5.02. The company has a current ratio of 1.71, a quick ratio of 0.82 and a debt-to-equity ratio of 0.22.
Analyst Upgrades and Downgrades
Several research firms recently issued reports on WALD. DA Davidson reduced their price target on Waldencast from $15.50 to $6.50 and set a “buy” rating for the company in a research note on Tuesday, May 28th. Telsey Advisory Group reaffirmed an “outperform” rating and set a $8.00 target price on shares of Waldencast in a report on Tuesday, May 21st.
About Waldencast
Waldencast plc operates in the beauty and wellness business. The company engages in developing, acquiring, accelerating, and scaling various brands. It provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians.
Recommended Stories
- Five stocks we like better than Waldencast
- Which Wall Street Analysts are the Most Accurate?
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- How to Choose Top Rated Stocks
- 2 Option Strategies to Maximize Profits in a Bear Market
- Consumer Staples Stocks, Explained
- Lululemon Stock Gears Up for a Massive Comeback Rally
Receive News & Ratings for Waldencast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waldencast and related companies with MarketBeat.com's FREE daily email newsletter.